|
Atkins Diet Legacy Continued By Dr. Salerno
There's another graduate from the Dr. Robert C. Atkins School of Nutrition I'd like to introduce you to today. His name is Dr. John P. Salerno and he worked directly with the late great one at The Atkins Center For Complementary Medicine beginning in July 2002 until Dr. Atkins' untimely death in 2004. But the indelible impression that was left upon Dr. Salerno is stronger than ever as we approach 2007. Dr. Salerno started his own holistic clinic imploring changes in diet and nutrition called The Salerno Center For Complementary Medicine where he uses the training he learned from Dr. Atkins to provide the highest quality of healthcare using a low-carb dietary approach along with the right mix of vitamins and minerals, detoxification methods, and all-natural hormone therapy. With 15 years of experience, which includes some teaching at the prestigious Yale Medical School, Dr.
Bayer, others settle with US over weight-loss ads
WASHINGTON, Jan 4 (Reuters) - Bayer AG and several smaller companies agreed to pay the U.S. government almost $26 million to settle allegations of false weight-loss advertising claims, the Federal Trade Commission said on Thursday. The settlements involve Bayer's One-A-Day WeightSmart multi-vitamin, as well as the diet pills CortiSlim, TrimSpa and Xenadrine EFX, which are made and sold by other companies. "You're not going to find weight loss in a bottle of pills," FTC Chairman Deborah Platt Majoras told reporters. "These ads are encouraging consumers to postpone the tougher choices that have to be made when one wants to lose weight." In the case of Bayer, the company will pay a $3.2 million civil penalty to settle FTC allegations that ads for One-A-Day WeightSmart multivitamins violated an earlier agency order requiring all health claims for One-A-Day brand vitamins to be supported by scientific evidence.
Medifast Declines Amid CEO Transition
Shares of Medifast Inc. continued to decline after the diet and nutrition products and services company said president and financial chief Michael McDevitt will become chief executive starting in March 2007. The stock declined $1.01, or nearly 9 percent, to $10.59 on the New York Stock Exchange, following Friday's decline. In a 52-week range, shares have traded in a range of $5.56 to $21.15. McDevitt replaces current Chief Executive Bradley MacDonald, who will retire from management but remain chairman of the board and also provide financial and management guidance. Meanwhile, investment weekly Barron's reported MacDonald allegedly posted information on the Internet touting Medifast on Yahoo Inc.'s finance message board. Barron's, citing sources close to the matter, also said company directors warned MacDonald last month to stop posting messages, saying such activity may violate fair disclosure regulations.
|
